Japanese authorities have approved the use of remdesivir, which was developed against Ebola, to treat patients infected with the coronavirus. This was announced on Thursday, May 7 by the Ministry of Health, Labor, and Welfare of the country. It is currently the first approved by the Japanese government to treat patients with positive COVID-19 tests.
According to the latest statistics from the Worldometer Bureau of Statistics, 15,253 cases of coronavirus infection have been recorded in Japan, while 556 patients have died and 4,496 have recovered.
Earlier, on May 1, it became known that the Food and Administration (FDA) under the US Department of Health and Human Services issued permission to use remdesivir in the treatment of coronavirus.
The decision to use this medicine was made after the American pharmaceutical company Gilead Sciences reported that the use of the reduces the recovery time of patients hospitalized with COVID-19 by 31% or four days. -19, began at the end of December last year. The focus of infection was the Chinese city of Wuhan. For several months, the disease has spread to more than 210 countries in the world. On March 11, WHO announced a coronavirus pandemic.
According to Worldometer data, on May 7, more than 3.84 million cases of the disease were registered on the planet, more than 265 thousand people died, 1.3 million were cured.